Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PRFX

PRF Technologies Ltd

May 26 • 04:00PM ET

1.34

-0.15 -10.07 %

Healthcare • Drug Manufacturers - Specialty & Generic • Israel • Nano • NASD

Today, 8:35 AMPRF Technologies' lead candidate PRF-110 matches approved ZYNRELEF in 72-hour analgesia in head-to-head preclinical pig study, supporting next-step development

Peers: TEVA RDY VTRS AMPH PRGO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.49	Insider Own	6.24%	Shs Outstand	0.84M	Perf Week	-12.42%
Market Cap	1.13M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.79M	Perf Month	-41.23%
Enterprise Value	-2.27M	PEG	-	EPS next Q	-	Inst Own	9.75%	Short Float	9.33%	Perf Quarter	-53.63%
Income	-4.84M	P/S	56.66	EPS this Y	-	Inst Trans	14.29%	Short Ratio	0.13	Perf Half Y	-68.90%
Sales	0.02M	P/B	0.13	EPS next Y	-	ROA	-	Short Interest	0.07M	Perf YTD	-58.24%
Book/sh	10.29	P/C	0.27	EPS next 5Y	-	ROE	-	52W High	17.95 -92.53%	Perf Year	-86.40%
Cash/sh	4.93	P/FCF	-	EPS past 3/5Y	80.39% 55.23%	ROIC	-56.63%	52W Low	1.28 4.69%	Perf 3Y	-99.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-4864.71%	Volatility	12.46% 8.39%	Perf 5Y	-99.96%
Dividend TTM	-	EV/Sales	-113.34	EPS Y/Y TTM	99.15%	Oper. Margin	-29335.29%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	-	Profit Margin	-28458.82%	RSI (14)	26.55	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.78	EPS Q/Q	-3.64%	SMA20	-22.50%	Beta	0.74	Target Price	240.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-36.90%	Rel Volume	0.16	Prev Close	1.49
Employees	7	LT Debt/Eq	0.00	Earnings	-	SMA200	-69.81%	Avg Volume	551.63K	Price	1.34
IPO	Sep 01, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-5.77% -	Trades		Volume	85,586	Change	-10.07%

Today 08:30AM	PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study (GlobeNewswire) -10.07%
Apr-28-26 08:00AM	PRF Technologies Announces FDA Clearance of IND Application for OcuRing-K Phase II Clinical Trial (GlobeNewswire) -10.92%
Apr-06-26 10:30AM	BC-Most Active Stocks (Associated Press) +20.48%
Mar-27-26 08:00AM	PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms (GlobeNewswire) -11.86%
Mar-17-26 08:30AM	PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements (GlobeNewswire) -6.20%
09:15AM	Loading…
Feb-18-26 09:15AM	PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy (GlobeNewswire)
Feb-11-26 08:30AM	PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base (GlobeNewswire) +8.47%
Jan-20-26 09:05AM	PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy (GlobeNewswire) -13.54%
Jan-16-26 11:39AM	PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push (Benzinga) +37.96%
Jan-15-26 04:05PM	PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms (GlobeNewswire)
Jan-12-26 09:00AM	PainReform's LayerBio's Drop-Less OcuRing-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies (GlobeNewswire) -5.55%
Jan-05-26 09:00AM	PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market (GlobeNewswire)
Dec-30-25 08:48AM	BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week (PR Newswire) -6.98%
Dec-10-25 08:30AM	PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities (GlobeNewswire)
Dec-02-25 09:15AM	PainReform Commences Development for OcuRing-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy (GlobeNewswire)
09:00AM	Loading…
Nov-12-25 09:00AM	PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis (GlobeNewswire) +9.26%
Nov-05-25 08:30AM	PainReform's DeepSolar, Developing "DeepSolar Predict" within the NVIDIA Connect Program, Featured in The Market Link's "Watchlist Interview" and Announces Progress Toward Pilot Projects (GlobeNewswire) +6.67%
Oct-01-25 09:27AM	PainReform Provides Business Update for the Six Months Ended June 30, 2025 (GlobeNewswire)
Aug-19-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +76.87%
08:30AM	PainReform/DeepSolar Accepted into NVIDIA Connect Program (GlobeNewswire)
Aug-13-25 08:30AM	PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System (GlobeNewswire) +7.12%
Jul-10-25 08:30AM	PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio (GlobeNewswire)
May-27-25 12:12PM	Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales (PR Newswire)
May-07-25 04:30PM	PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar Platform to Optimize One of Romania's Largest Solar Projects (GlobeNewswire) -8.49%
Apr-10-25 08:30AM	PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market (GlobeNewswire) +18.13%
Apr-07-25 05:00PM	PainReform Provides Year-End Business Update (GlobeNewswire) -8.13% -8.94%
Mar-06-25 11:06AM	PainReform completes acquisition of DeepSolar (TipRanks)
Mar-05-25 11:00AM	PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics (GlobeNewswire)
Feb-18-25 08:30AM	PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity (GlobeNewswire) +31.56%
Dec-28-24 09:17AM	PainReform Faces Setback in Phase 3 Trial for PRF-110 (TipRanks)
08:30AM	Loading…
Dec-27-24 08:30AM	PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 (GlobeNewswire) -28.57%
Nov-20-24 08:30AM	PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial (GlobeNewswire) -25.71%
Nov-07-24 05:00PM	PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (GlobeNewswire) +7.16%
Oct-25-24 09:25AM	PainReform cut to Hold at Maxim amid changed market dynamics (TipRanks) -8.87%
Sep-11-24 08:30AM	PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 (GlobeNewswire) -10.38%
Sep-10-24 09:46AM	PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds (GlobeNewswire) -33.33%
Sep-09-24 12:14PM	Upcoming Stock Splits This Week (September 9 to September 13) Stay Invested (TipRanks)
Aug-21-24 08:30AM	PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures (GlobeNewswire)
Aug-20-24 08:30AM	PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study (GlobeNewswire) -15.20%
Aug-15-24 08:00AM	PainReform Provides Business Update for the Second Quarter of 2024 (GlobeNewswire)
Aug-12-24 09:00AM	PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects (GlobeNewswire)
Aug-07-24 10:00AM	PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses (GlobeNewswire)
Aug-05-24 09:00AM	PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110 (GlobeNewswire) -12.72%
Aug-01-24 08:30AM	PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature (GlobeNewswire)
Jul-24-24 08:30AM	PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing (GlobeNewswire) -6.36%
Jun-26-24 08:00AM	PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 (GlobeNewswire)
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -5.49%
May-31-24 04:15PM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-15-24 10:54PM	PRFX Stock Earnings: PainReform Misses EPS for Q1 2024 (InvestorPlace) -6.31%
04:05PM	PainReform Provides Business Update for the First Quarter of 2024 (GlobeNewswire)
May-08-24 08:30AM	PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com (GlobeNewswire) -6.43%
Apr-18-24 02:19PM	PainReform Announces Closing of $4 Million Public Offering (GlobeNewswire)
Apr-16-24 08:00AM	PainReform Announces Pricing of $4 Million Public Offering (GlobeNewswire) -17.42%
Apr-09-24 10:30AM	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions (Benzinga) -13.21%
09:00AM	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions (GlobeNewswire)
Apr-02-24 10:00AM	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug (Benzinga)
08:30AM	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-01-24 08:00AM	PainReform Provides Year-End Business Update (GlobeNewswire) +21.42%
Jan-22-24 08:30AM	PainReform to Present at the Microcap Conference in Atlantic City (GlobeNewswire) -7.37%
Jan-03-24 08:30AM	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief (GlobeNewswire)
Dec-26-23 06:00PM	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds (GlobeNewswire)
Nov-15-23 04:05PM	PainReform Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -5.33%
Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire) +44.72%
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-22 07:00AM	PainReform Provides Business Update for the First Quarter of 2022 (GlobeNewswire) +12.84%
Apr-12-22 09:00AM	PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th (GlobeNewswire)
Mar-21-22 09:25AM	PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th (GlobeNewswire) +39.64%
Mar-17-22 08:00AM	PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 (GlobeNewswire) -14.17%
Dec-14-21 08:30AM	PainReform CEO to Participate in the Benzinga All Access Event on December 16th (GlobeNewswire) -5.36%
Nov-22-21 11:58AM	PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today (InvestorPlace)
07:02AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-16-21 08:00AM	PainReform Provides Business Update for the Third Quarter of 2021 (GlobeNewswire) -9.45%
Oct-14-21 08:30AM	PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Aug-16-21 08:00AM	PainReform Provides Business Update for the Second Quarter of 2021 (GlobeNewswire) -5.58%
Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? (Insider Monkey) -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate (Simply Wall St.)

PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Executive ChairmanDr. Ehud Geller Ph.D.

Ph.D.Dr. Sigal Aviel eMBA

Interim CEO & DirectorMr. Efraim Cohen-Arazi

Executive Vice President of DevelopmentDr. Stephen A. Cooper D.M.D Ph.D.

Vice President of Pharmaceutical OperationsMs. Rita Keynan M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRFX

PRF Technologies Ltd

Upgrade your Finviz experience